Globally, 415 million people are living with DIABETES & which is a leading cause of death.
Dipeptidyl peptidase IV (DPP-4) inhibitors are ubiquitous enzymes that act on incretin hormones, which maintain glucose homeostasis by increasing insulin secretion and decreasing glucagon secretion.
Most of the DPP-4 inhibitors have minimal to no interactions with other drugs because of their pharmacokinetic properties.
- Class of medications: Oral antidiabetic agents/ incretin enhancers – Dipeptidyl peptidase IV (DPP-IV) inhibitors
- Inhibits dipeptidyl peptidase-4 and prevents degradation of glucagon-like peptide-1 in patients with type-2 diabetes mellitus.
- Rapidly & well-absorbed with an absolute bioavailability of 85%.
- No accumulation of the drug is seen because of the short elimination half-life.
Vildagliptin 50 mg
- Type 2 Diabetes